{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["5FU", "ABCC1", "PIK3CA", "Saudi colorectal cancer", "drug resistance", "kinase pathway profiling"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "33440689", "DateCompleted": {"Year": "2021", "Month": "09", "Day": "10"}, "DateRevised": {"Year": "2021", "Month": "09", "Day": "10"}, "Article": {"ArticleDate": [{"Year": "2021", "Month": "01", "Day": "11"}], "Language": ["eng"], "ELocationID": ["334", "10.3390/molecules26020334"], "Journal": {"ISSN": "1420-3049", "JournalIssue": {"Volume": "26", "Issue": "2", "PubDate": {"Year": "2021", "Month": "Jan", "Day": "11"}}, "Title": "Molecules (Basel, Switzerland)", "ISOAbbreviation": "Molecules"}, "ArticleTitle": "Chemosensitization of HT29 and HT29-5FU Cell Lines by a Combination of a Multi-Tyrosine Kinase Inhibitor and 5FU Downregulates ABCC1 and Inhibits PIK3CA in Light of Their Importance in Saudi Colorectal Cancer.", "Abstract": {"AbstractText": ["Colorectal cancer (CRC) remains one of the main causes of death worldwide and in Saudi Arabia. The toxicity and the development of resistance against 5 fluorouracil 5FU pose increasing therapeutic difficulties, which necessitates the development of personalized drugs and drug combinations.", "First, to determine the most important kinases and kinase pathways, and the amount of ABC transporters and KRAS in samples taken from Saudi CRC patients. Second, to investigate the chemosensitizing effect of LY294002 and HAA<sub>2020</sub> and their combinations with 5FU on HT29, HT29-5FU, HCT116, and HCT116-5FU CRC cells, their effect on the three ABC transporters, cell cycle, and apoptosis, in light of the important kinase pathways resulting from the first part of this study.", "The PamChip<sup>\u00ae</sup> peptide micro-array profiling was used to determine the level of kinase and targets in the Saudi CRC samples. Next, RT-PCR, MTT cytotoxicity, Western blotting, perturbation of cell cycle, annexin V, and immunofluorescence assays were used to investigate the effect on CRC, MRC5, and HUVEC cells.", "The kinase activity profiling highlighted the importance of the PI3K/AKT, MAPK, and the growth factors pathways in the Saudi CRC samples. PIK3CA was the most overexpressed, and it was associated with increased level of mutated KRAS and the three ABC transporters, especially ABCC1 in the Saudi samples. Next, combining HAA<sub>2020</sub> with 5FU exhibited the best synergistic and resistance-reversal effect in the four CRC cells, and the highest selectivity indices compared to MRC5 and HUVEC normal cells. Additionally, HAA<sub>2020</sub> with 5FU exerted significant inhibition of ABCC1 in the four CRC cells, and inhibition of PIK3CA/AKT/MAPK7/ERK in HT29 and HT29-5FU cells. The combination also inhibited EGFR, increased the preG<sub>1</sub>/S cell cycle phases, apoptosis, and caspase 8 in HT29 cells, while it increased the G<sub>1</sub> phase, p21/p27, and apoptosis in HT29-5FU cells.", "We have combined the PamChip kinase profiling of Saudi CRC samples with in vitro drug combination studies in four CRC cells, highlighting the importance of targeting PIK3CA and ABCC1 for Saudi CRC patients, especially given that the overexpression of PIK3CA mutations was previously linked with the lack of activity for the anti-EGFRs as first line treatment for CRC patients. The combination of HAA<sub>2020</sub> and 5FU has selectively sensitized the four CRC cells to 5FU and could be further studied."]}, "AuthorList": [{"Identifier": ["0000-0003-4770-9319"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacology and Toxicology, College of Pharmacy, Umm Al-Qura University, Makkah 21955, Saudi Arabia."}, {"Identifier": [], "Affiliation": "Medicinal and Aromatic Plants Research Institute, National Center for Research, Khartoum 2424, Sudan."}], "LastName": "Abdalla", "ForeName": "Ashraf N", "Initials": "AN"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacology and Toxicology, College of Pharmacy, Umm Al-Qura University, Makkah 21955, Saudi Arabia."}], "LastName": "Malki", "ForeName": "Waleed H", "Initials": "WH"}, {"Identifier": ["0000-0001-7362-789X"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Breast Cancer Research, Department of Molecular Oncology, King Faisal Specialist Hospital and Research Centre, Riyadh 11211, Saudi Arabia."}, {"Identifier": [], "Affiliation": "Department of Biochemistry and Molecular Medicine, School of Medicine and Health Sciences (SMHS), George Washington University, Washington, DC 20073, USA."}], "LastName": "Qattan", "ForeName": "Amal", "Initials": "A"}, {"Identifier": ["0000-0002-9832-3224"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacology and Toxicology, College of Pharmacy, Umm Al-Qura University, Makkah 21955, Saudi Arabia."}, {"Identifier": [], "Affiliation": "Department of Pharmacology and Toxicology, Faculty of Medicine, Umm Al-Qura University, Makkah 21955, Saudi Arabia."}], "LastName": "Shahid", "ForeName": "Imran", "Initials": "I"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacology and Toxicology, College of Pharmacy, Umm Al-Qura University, Makkah 21955, Saudi Arabia."}, {"Identifier": [], "Affiliation": "Department of Pharmacology and Toxicology, Faculty of Medicine, Umm Al-Qura University, Makkah 21955, Saudi Arabia."}], "LastName": "Hossain", "ForeName": "Mohammad Akbar", "Initials": "MA"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacology and Toxicology, College of Pharmacy, Umm Al-Qura University, Makkah 21955, Saudi Arabia."}], "LastName": "Ahmed", "ForeName": "Muhammad", "Initials": "M"}], "GrantList": [{"GrantID": "13-MED873-10", "Agency": "King Abdulaziz City for Science and Technology", "Country": ""}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Molecules", "NlmUniqueID": "100964009", "ISSNLinking": "1420-3049"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Antimetabolites, Antineoplastic"}, {"RegistryNumber": "0", "NameOfSubstance": "Chromones"}, {"RegistryNumber": "0", "NameOfSubstance": "Morpholines"}, {"RegistryNumber": "0", "NameOfSubstance": "Multidrug Resistance-Associated Proteins"}, {"RegistryNumber": "0", "NameOfSubstance": "Phosphoinositide-3 Kinase Inhibitors"}, {"RegistryNumber": "0", "NameOfSubstance": "Protein Kinase Inhibitors"}, {"RegistryNumber": "31M2U1DVID", "NameOfSubstance": "2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one"}, {"RegistryNumber": "EC 2.7.1.137", "NameOfSubstance": "Class I Phosphatidylinositol 3-Kinases"}, {"RegistryNumber": "EC 2.7.1.137", "NameOfSubstance": "PIK3CA protein, human"}, {"RegistryNumber": "U3P01618RT", "NameOfSubstance": "Fluorouracil"}, {"RegistryNumber": "Y49M64GZ4Q", "NameOfSubstance": "multidrug resistance-associated protein 1"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Adult"}, {"QualifierName": [], "DescriptorName": "Aged"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Antimetabolites, Antineoplastic"}, {"QualifierName": ["drug effects"], "DescriptorName": "Apoptosis"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Chromones"}, {"QualifierName": ["antagonists & inhibitors", "metabolism"], "DescriptorName": "Class I Phosphatidylinositol 3-Kinases"}, {"QualifierName": ["drug therapy", "epidemiology", "metabolism"], "DescriptorName": "Colorectal Neoplasms"}, {"QualifierName": ["drug effects"], "DescriptorName": "Drug Resistance, Neoplasm"}, {"QualifierName": [], "DescriptorName": "Drug Synergism"}, {"QualifierName": [], "DescriptorName": "Female"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Fluorouracil"}, {"QualifierName": [], "DescriptorName": "HCT116 Cells"}, {"QualifierName": [], "DescriptorName": "HT29 Cells"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Male"}, {"QualifierName": [], "DescriptorName": "Middle Aged"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Morpholines"}, {"QualifierName": ["antagonists & inhibitors", "metabolism"], "DescriptorName": "Multidrug Resistance-Associated Proteins"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Phosphoinositide-3 Kinase Inhibitors"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Protein Kinase Inhibitors"}, {"QualifierName": ["epidemiology"], "DescriptorName": "Saudi Arabia"}], "CoiStatement": "The authors declare no conflict of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Rawla P., Sunkara T., Barsouk A. Epidemiology of colorectal cancer: Incidence, mortality, survival, and risk factors. Prz. Gastroenterol. 2019;14:89\u2013103. doi: 10.5114/pg.2018.81072.", "ArticleIdList": ["10.5114/pg.2018.81072", "PMC6791134", "31616522"]}, {"Citation": "Zeyad Saeed Al-Shahrani A.I.A.-R., Amal Nasser Al-Madouj M.S.H.  Cancer Incidence Report Saudi Arabia. Saudi Health Council; Riyadh, Saudi Arabia: 2017.  [(accessed on 8 January 2021)].  Available online:  https://nhic.gov.sa/eServices/Documents/2014.pdf."}, {"Citation": "El Zouhairi M., Charabaty A., Pishvaian M.J. Molecularly targeted therapy for metastatic colon cancer: Proven treatments and promising new agents. Gastrointest. Cancer Res. 2011;4:15\u201321.", "ArticleIdList": ["PMC3070284", "21464866"]}, {"Citation": "Vodenkova S., Buchler T., Cervena K., Veskrnova V., Vodicka P., Vymetalkova V. 5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future. Pharmacol. Ther. 2020;206:107447. doi: 10.1016/j.pharmthera.2019.107447.", "ArticleIdList": ["10.1016/j.pharmthera.2019.107447", "31756363"]}, {"Citation": "Zhang N., Yin Y., Xu S.J., Chen W.S. 5-Fluorouracil: Mechanisms of resistance and reversal strategies. Molecules. 2008;13:1551\u20131569. doi: 10.3390/molecules13081551.", "ArticleIdList": ["10.3390/molecules13081551", "PMC6244944", "18794772"]}, {"Citation": "Giordano G., Febbraro A., Venditti M., Campidoglio S., Olivieri N., Raieta K., Parcesepe P., Imbriani G.C., Remo A., Pancione M. Targeting angiogenesis and tumor microenvironment in metastatic colorectal cancer: Role of aflibercept. Gastroenterol. Res. Pract. 2014;2014:526178. doi: 10.1155/2014/526178.", "ArticleIdList": ["10.1155/2014/526178", "PMC4130202", "25136356"]}, {"Citation": "Mousa L., Salem M.E., Mikhail S. Biomarkers of Angiogenesis in Colorectal Cancer. Biomark. Cancer. 2015;7(Suppl. 1):13\u201319. doi: 10.4137/BIC.S25250.", "ArticleIdList": ["10.4137/BIC.S25250", "PMC4624093", "26543385"]}, {"Citation": "Hamada T., Nowak J.A., Ogino S. PIK3CA mutation and colorectal cancer precision medicine. Oncotarget. 2017;8:22305\u201322306. doi: 10.18632/oncotarget.15724.", "ArticleIdList": ["10.18632/oncotarget.15724", "PMC5410221", "28423591"]}, {"Citation": "Milano G. PIK3CA mutations and specific treatment: Do not forget lessons from RAS mutations and EGFR targeting. Cancer Chemother. Pharmacol. 2020;85:473\u2013474. doi: 10.1007/s00280-019-04016-9.", "ArticleIdList": ["10.1007/s00280-019-04016-9", "31970497"]}, {"Citation": "Lopez A., Harada K., Vasilakopoulou M., Shanbhag N., Ajani J.A. Targeting Angiogenesis in Colorectal Carcinoma. Drugs. 2019;79:63\u201374. doi: 10.1007/s40265-018-1037-9.", "ArticleIdList": ["10.1007/s40265-018-1037-9", "30617958"]}, {"Citation": "Vergoulidou M. More than a Decade of Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: What We Have Learned and What the Future Holds. Biomark. Insights. 2015;10(Suppl. 3):33\u201340. doi: 10.4137/BMI.S22436.", "ArticleIdList": ["10.4137/BMI.S22436", "PMC4599592", "26483606"]}, {"Citation": "Estrada C.C., Maldonado A., Mallipattu S.K. Therapeutic Inhibition of VEGF Signaling and Associated Nephrotoxicities. J. Am. Soc. Nephrol. 2019;30:187\u2013200. doi: 10.1681/ASN.2018080853.", "ArticleIdList": ["10.1681/ASN.2018080853", "PMC6362621", "30642877"]}, {"Citation": "Garc\u00eda-Aranda M., Redondo M. Targeting Receptor Kinases in Colorectal Cancer. Cancers. 2019;11:433. doi: 10.3390/cancers11040433.", "ArticleIdList": ["10.3390/cancers11040433", "PMC6521260", "30934752"]}, {"Citation": "Alyabsi M., Alhumaid A., Allah-Bakhsh H., Alkelya M., Aziz M.A. Colorectal cancer in Saudi Arabia as the proof-of-principle model for implementing strategies of predictive, preventive, and personalized medicine in healthcare. EPMA J. 2020;11:119\u2013131. doi: 10.1007/s13167-019-00186-x.", "ArticleIdList": ["10.1007/s13167-019-00186-x", "PMC7028887", "32140189"]}, {"Citation": "Eldai H., Periyasamy S., Al Qarni S., Al Rodayyan M., Muhammed Mustafa S., Deeb A., Al Sheikh E., Afzal M., Johani M., Yousef Z., et al. Novel genes associated with colorectal cancer are revealed by high resolution cytogenetic analysis in a patient specific manner. PLoS ONE. 2013;8:e76251.", "ArticleIdList": ["PMC3813709", "24204606"]}, {"Citation": "Alhadheq A.M., Purusottapatnam Shaik J., Alamri A., Aljebreen A.M., Alharbi O., Almadi M.A., Alhadeq F., Azzam N.A., Semlali A., Alanazi M., et al. The Effect of Poly(ADP-ribose) Polymerase-1 Gene 3\u2019Untranslated Region Polymorphism in Colorectal Cancer Risk among Saudi Cohort. Dis. Markers. 2016;2016:8289293. doi: 10.1155/2016/8289293.", "ArticleIdList": ["10.1155/2016/8289293", "PMC5055945", "27746584"]}, {"Citation": "Al-Kuraya K.S., Bavi P.P., Ezzat A.A., Al-Dayel F.A., Uddin S., Atizado V.L., Al-Jomah N.A., Amr S.S., Sheikh S.S., Sauter G., et al. Colorectal carcinoma from Saudi Arabia. Analysis of MLH-1, MSH-2 and p53 genes by immunohistochemistry and tissue microarray analysis. Saudi Med. J. 2006;27:323\u2013328.", "ArticleIdList": ["16532091"]}, {"Citation": "Hu T., Li Z., Gao C.Y., Cho C.H. Mechanisms of drug resistance in colon cancer and its therapeutic strategies. World J. Gastroenterol. 2016;22:6876\u20136889. doi: 10.3748/wjg.v22.i30.6876.", "ArticleIdList": ["10.3748/wjg.v22.i30.6876", "PMC4974586", "27570424"]}, {"Citation": "Szakacs G., Annereau J.P., Lababidi S., Shankavaram U., Arciello A., Bussey K.J., Reinhold W., Guo Y., Kruh G.D., Reimers M., et al. Predicting drug sensitivity and resistance: Profiling ABC transporter genes in cancer cells. Cancer Cell. 2004;6:129\u2013137. doi: 10.1016/j.ccr.2004.06.026.", "ArticleIdList": ["10.1016/j.ccr.2004.06.026", "15324696"]}, {"Citation": "Choi C.H. ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal. Cancer Cell Int. 2005;5:30. doi: 10.1186/1475-2867-5-30.", "ArticleIdList": ["10.1186/1475-2867-5-30", "PMC1277830", "16202168"]}, {"Citation": "Qutub R.M., Al-Ghafari A.B., Al Doghaither H.A., Omar U.M., Ghulam J.M. Increased expressions of cellular ATP-binding cassette transporters may be a promising diagnostic marker for colorectal cancer. Saudi Med. J. 2020;41:834\u2013840. doi: 10.15537/smj.2020.8.25187.", "ArticleIdList": ["10.15537/smj.2020.8.25187", "PMC7502964", "32789424"]}, {"Citation": "Al-Ghafari A.B., Qahtani A.M.A., Alturki S.N., Doghaither H.A.A., Elmorsy E.M., Tashkandi H.M., Abusanad A.M., Alkhayyat S.S., Omar U.M., Zeeneldin A.A. Association between MDR1 polymorphisms and XELIRI and XELOX chemoresistance in Saudi patients with colorectal cancer. Oncol. Lett. 2020;20:155. doi: 10.3892/ol.2020.12016.", "ArticleIdList": ["10.3892/ol.2020.12016", "PMC7471754", "32934723"]}, {"Citation": "Kim J.H., Park J.M., Roh Y.J., Kim I.W., Hasan T., Choi M.G. Enhanced efficacy of photodynamic therapy by inhibiting ABCG2 in colon cancers. BMC Cancer. 2015;15:504. doi: 10.1186/s12885-015-1514-4.", "ArticleIdList": ["10.1186/s12885-015-1514-4", "PMC4494642", "26149077"]}, {"Citation": "Aires V., Colin D.J., Doreau A., Di Pietro A., Heydel J.M., Artur Y., Latruffe N., Delmas D. P-Glycoprotein 1 Affects Chemoactivities of Resveratrol against Human Colorectal Cancer Cells. Nutrients. 2019;11:2098. doi: 10.3390/nu11092098.", "ArticleIdList": ["10.3390/nu11092098", "PMC6770091", "31487863"]}, {"Citation": "Park J.W., Jung K.H., Byun Y., Lee J.H., Moon S.H., Cho Y.S., Lee K.H. ATP-binding Cassette Transporters Substantially Reduce Estimates of ALDH-positive Cancer Cells based on Aldefluor and AldeRed588 Assays. Sci. Rep. 2019;9:6462. doi: 10.1038/s41598-019-42954-9.", "ArticleIdList": ["10.1038/s41598-019-42954-9", "PMC6478741", "31015586"]}, {"Citation": "Wang T., Chen Z., Zhu Y., Pan Q., Liu Y., Qi X., Jin L., Jin J., Ma X., Hua D. Inhibition of transient receptor potential channel 5 reverses 5-Fluorouracil resistance in human colorectal cancer cells. J. Biol. Chem. 2015;290:448\u2013456. doi: 10.1074/jbc.M114.590364.", "ArticleIdList": ["10.1074/jbc.M114.590364", "PMC4281746", "25404731"]}, {"Citation": "Mohammed A.A., Mirza A.A., Hani E.T., Mirza A.A., Alsawaf E.H. Colorectal Cancer: Molecular Classification And Clinical Application. World J. Res. Rev. 2016;3:5\u20139."}, {"Citation": "Garc\u00eda-Campos M.A., Espinal-Enr\u00edquez J., Hern\u00e1ndez-Lemus E. Pathway Analysis: State of the Art. Front. Physiol. 2015;6:383. doi: 10.3389/fphys.2015.00383.", "ArticleIdList": ["10.3389/fphys.2015.00383", "PMC4681784", "26733877"]}, {"Citation": "Hilhorst M.H., Houkes L., Korsten H., Mommersteeg M., Trapman J., Ruijtenbeek R. Direct Detection of AKT/PKB Activity in a Pten Knock out Mouse Model Using Dynamic Peptide Microarrays. AACR; Philadelphia, PA, USA: 2011."}, {"Citation": "Chirumamilla C.S., Fazil M., Perez-Novo C., Rangarajan S., de Wijn R., Ramireddy P., Verma N.K., Vanden Berghe W. Profiling Activity of Cellular Kinases in Migrating T-Cells. Methods Mol. Biol. 2019;1930:99\u2013113.", "ArticleIdList": ["30610604"]}, {"Citation": "Hilhorst R., Houkes L., Mommersteeg M., Musch J., van den Berg A., Ruijtenbeek R. Peptide microarrays for profiling of serine/threonine kinase activity of recombinant kinases and lysates of cells and tissue samples. Methods Mol. Biol. 2013;977:259\u2013271.", "ArticleIdList": ["23436369"]}, {"Citation": "Abdalla A.N., Qattan A., Malki W.H., Shahid I., Hossain M.A., Ahmed M. Significance of Targeting VEGFR-2 and Cyclin D1 in Luminal-A Breast Cancer. Molecules. 2020;25:4606. doi: 10.3390/molecules25204606.", "ArticleIdList": ["10.3390/molecules25204606", "PMC7594023", "33050377"]}, {"Citation": "Jin H., Dan H.G., Rao G.-W. Research progress in quinazoline derivatives as multi-target tyrosine kinase inhibitors. Heterocycl. Commun. 2018;24:1\u201310. doi: 10.1515/hc-2017-0066.", "ArticleIdList": ["10.1515/hc-2017-0066"]}, {"Citation": "Solyanik G.I. Quinazoline compounds for antitumor treatment. Exp. Oncol. 2019;41:3\u20136. doi: 10.32471/exp-oncology.2312-8852.vol-41-no-1.12414.", "ArticleIdList": ["10.32471/exp-oncology.2312-8852.vol-41-no-1.12414", "30932417"]}, {"Citation": "Gao H.L., Gupta P., Cui Q., Ashar Y.V., Wu Z.X., Zeng L., Lei Z.N., Teng Q.X., Ashby C.R., Jr., Guan Y., et al. Sapitinib Reverses Anticancer Drug Resistance in Colon Cancer Cells Overexpressing the ABCB1 Transporter. Front. Oncol. 2020;10:574861. doi: 10.3389/fonc.2020.574861.", "ArticleIdList": ["10.3389/fonc.2020.574861", "PMC7581728", "33163405"]}, {"Citation": "Alkahtani H.M., Abdalla A.N., Obaidullah A.J., Alanazi M.M., Almehizia A.A., Alanazi M.G., Ahmed A.Y., Alwassil O.I., Darwish H.W., Abdel-Aziz A.A., et al. Synthesis, cytotoxic evaluation, and molecular docking studies of novel quinazoline derivatives with benzenesulfonamide and anilide tails: Dual inhibitors of EGFR/HER2. Bioorg. Chem. 2020;95:103461. doi: 10.1016/j.bioorg.2019.103461.", "ArticleIdList": ["10.1016/j.bioorg.2019.103461", "31838290"]}, {"Citation": "Dussaq A., Anderson J.C., Willey C.D., Almeida J.S. Mechanistic Parameterization of the Kinomic Signal in Peptide Arrays. J. Proteom. Bioinform. 2016;9:151\u2013157. doi: 10.4172/jpb.1000401.", "ArticleIdList": ["10.4172/jpb.1000401", "PMC5010871", "27601856"]}, {"Citation": "Jean S., Kiger A.A. Classes of phosphoinositide 3-kinases at a glance. Pt 5J. Cell Sci. 2014;127:923\u2013928. doi: 10.1242/jcs.093773.", "ArticleIdList": ["10.1242/jcs.093773", "PMC3937771", "24587488"]}, {"Citation": "Fransson S., Abel F., Kogner P., Martinsson T., Ejesk\u00e4r K. Stage-dependent expression of PI3K/Akt-pathway genes in neuroblastoma. Int. J. Oncol. 2013;42:609\u2013616. doi: 10.3892/ijo.2012.1732.", "ArticleIdList": ["10.3892/ijo.2012.1732", "23232578"]}, {"Citation": "He Q., Xu Q., Wu W., Chen L., Sun W., Ying J. Comparison of KRAS and PIK3CA gene status between primary tumors and paired metastases in colorectal cancer. Onco Targets Ther. 2016;9:2329\u20132335. doi: 10.2147/OTT.S97668.", "ArticleIdList": ["10.2147/OTT.S97668", "PMC4846063", "27143928"]}, {"Citation": "Al-Kuraya K.S. KRAS and TP53 mutations in colorectal carcinoma. Saudi J. Gastroenterol. 2009;15:217\u2013219. doi: 10.4103/1319-3767.56087.", "ArticleIdList": ["10.4103/1319-3767.56087", "PMC2981835", "19794264"]}, {"Citation": "Sanchez V.E., Nichols C., Kim H.N., Gang E.J., Kim Y.M. Targeting PI3K Signaling in Acute Lymphoblastic Leukemia. Int. J. Mol. Sci. 2019;20:412. doi: 10.3390/ijms20020412.", "ArticleIdList": ["10.3390/ijms20020412", "PMC6358886", "30669372"]}, {"Citation": "The PI3K\u03b1 Inhibitor Alpelisib Has Activity in PIK3CA-altered Tumors. Cancer Discov. 2018;8:7. doi: 10.1158/2159-8290.CD-RW2018-027.", "ArticleIdList": ["10.1158/2159-8290.CD-RW2018-027", "29453241"]}, {"Citation": "Surawska H., Ma P.C., Salgia R. The role of ephrins and Eph receptors in cancer. Cytokine Growth Factor Rev. 2004;15:419\u2013433. doi: 10.1016/j.cytogfr.2004.09.002.", "ArticleIdList": ["10.1016/j.cytogfr.2004.09.002", "15561600"]}, {"Citation": "Cortina C., Palomo-Ponce S., Iglesias M., Fern\u00e1ndez-Masip J.L., Vivancos A., Whissell G., Hum\u00e0 M., Peir\u00f3 N., Gallego L., Jonkheer S., et al. EphB-ephrin-B interactions suppress colorectal cancer progression by compartmentalizing tumor cells. Nat. Genet. 2007;39:1376\u20131383. doi: 10.1038/ng.2007.11.", "ArticleIdList": ["10.1038/ng.2007.11", "17906625"]}, {"Citation": "Herath N.I., Boyd A.W. The role of Eph receptors and ephrin ligands in colorectal cancer. Int. J. Cancer. 2010;126:2003\u20132011. doi: 10.1002/ijc.25147.", "ArticleIdList": ["10.1002/ijc.25147", "20039322"]}, {"Citation": "Baron W., Shattil S.J., ffrench-Constant C. The oligodendrocyte precursor mitogen PDGF stimulates proliferation by activation of alpha(v)beta3 integrins. EMBO J. 2002;21:1957\u20131966. doi: 10.1093/emboj/21.8.1957.", "ArticleIdList": ["10.1093/emboj/21.8.1957", "PMC125971", "11953315"]}, {"Citation": "Heldin C.H., Ostman A., R\u00f6nnstrand L. Signal transduction via platelet-derived growth factor receptors. Biochim. Biophys. Acta. 1998;1378:F79\u2013F113. doi: 10.1016/S0304-419X(98)00015-8.", "ArticleIdList": ["10.1016/S0304-419X(98)00015-8", "9739761"]}, {"Citation": "McCubrey J.A., Lahair M.M., Franklin R.A. Reactive oxygen species-induced activation of the MAP kinase signaling pathways. Antioxid. Redox. Signal. 2006;8:1775\u20131789. doi: 10.1089/ars.2006.8.1775.", "ArticleIdList": ["10.1089/ars.2006.8.1775", "16987031"]}, {"Citation": "Paulsen C.E., Truong T.H., Garcia F.J., Homann A., Gupta V., Leonard S.E., Carroll K.S. Peroxide-dependent sulfenylation of the EGFR catalytic site enhances kinase activity. Nat. Chem. Biol. 2011;8:57\u201364. doi: 10.1038/nchembio.736.", "ArticleIdList": ["10.1038/nchembio.736", "PMC3528018", "22158416"]}, {"Citation": "Lander H.M., Ogiste J.S., Teng K.K., Novogrodsky A. p21ras as a common signaling target of reactive free radicals and cellular redox stress. J. Biol. Chem. 1995;270:21195\u201321198. doi: 10.1074/jbc.270.36.21195.", "ArticleIdList": ["10.1074/jbc.270.36.21195", "7673152"]}, {"Citation": "Chen H.J., Jiang Y.L., Lin C.M., Tsai S.C., Peng S.F., Fushiya S., Hour M.J., Yang J.S. Dual inhibition of EGFR and c-Met kinase activation by MJ-56 reduces metastasis of HT29 human colorectal cancer cells. Int. J. Oncol. 2013;43:141\u2013150. doi: 10.3892/ijo.2013.1941.", "ArticleIdList": ["10.3892/ijo.2013.1941", "23677180"]}, {"Citation": "Li H.Y., Li M., Luo C.C., Wang J.Q., Zheng N. Lactoferrin Exerts Antitumor Effects by Inhibiting Angiogenesis in a HT29 Human Colon Tumor Model. J. Agric. Food Chem. 2017;65:10464\u201310472. doi: 10.1021/acs.jafc.7b03390.", "ArticleIdList": ["10.1021/acs.jafc.7b03390", "29112400"]}, {"Citation": "SiShi Li E.B. Lihua Wu, Jeffrey, D.; Bjorge, Donald, J.; Fujita, Shudong Zhu, EGFR and HER2 levels are frequently elevated in colon cancer cells. Discov. Rep. 2014;1:1\u20138."}, {"Citation": "Dittmann A., Werner T., Chung C.W., Savitski M.M., F\u00e4lth Savitski M., Grandi P., Hopf C., Lindon M., Neubauer G., Prinjha R.K., et al. The commonly used PI3-kinase probe LY294002 is an inhibitor of BET bromodomains. ACS Chem. Biol. 2014;9:495\u2013502. doi: 10.1021/cb400789e.", "ArticleIdList": ["10.1021/cb400789e", "24533473"]}, {"Citation": "Yang S.Y., Miah A., Sales K.M., Fuller B., Seifalian A.M., Winslet M. Inhibition of the p38 MAPK pathway sensitises human colon cancer cells to 5-fluorouracil treatment. Int. J. Oncol. 2011;38:1695\u20131702. doi: 10.3892/ijo.2011.982.", "ArticleIdList": ["10.3892/ijo.2011.982", "21424124"]}, {"Citation": "Blain S.W., Scher H.I., Cordon-Cardo C., Koff A. p27 as a target for cancer therapeutics. Cancer Cell. 2003;3:111\u2013115. doi: 10.1016/S1535-6108(03)00026-6.", "ArticleIdList": ["10.1016/S1535-6108(03)00026-6", "12620406"]}, {"Citation": "Zirbes T.K., Baldus S.E., Moenig S.P., Nolden S., Kunze D., Shafizadeh S.T., Schneider P.M., Thiele J., Hoelscher A.H., Dienes H.P. Prognostic impact of p21/waf1/cip1 in colorectal cancer. Int. J. Cancer. 2000;89:14\u201318. doi: 10.1002/(SICI)1097-0215(20000120)89:1<14::AID-IJC3>3.0.CO;2-L.", "ArticleIdList": ["10.1002/(SICI)1097-0215(20000120)89:1<14::AID-IJC3>3.0.CO;2-L", "10719725"]}, {"Citation": "Donjerkovic D., Scott D.W. Regulation of the G1 phase of the mammalian cell cycle. Cell Res. 2000;10:1\u201316. doi: 10.1038/sj.cr.7290031.", "ArticleIdList": ["10.1038/sj.cr.7290031", "10765979"]}, {"Citation": "Eid S.Y., Althubiti M.A., Abdallah M.E., Wink M., El-Readi M.Z. The carotenoid fucoxanthin can sensitize multidrug resistant cancer cells to doxorubicin via induction of apoptosis, inhibition of multidrug resistance proteins and metabolic enzymes. Phytomedicine. 2020;77:153280. doi: 10.1016/j.phymed.2020.153280.", "ArticleIdList": ["10.1016/j.phymed.2020.153280", "32712543"]}, {"Citation": "Abdalla A.N., Abdallah M.E., Aslam A., Bader A., Vassallo A., Tommasi N., Malki W.H., Gouda A.M., Mukhtar M.H., El-Readi M.Z., et al. Synergistic Anti Leukemia Effect of a Novel Hsp90 and a Pan Cyclin Dependent Kinase Inhibitors. Molecules. 2020;25:2220. doi: 10.3390/molecules25092220.", "ArticleIdList": ["10.3390/molecules25092220", "PMC7248782", "32397330"]}, {"Citation": "Abdalla A.N., Shaheen U., Abdallah Q.M.A., Flamini G., Bkhaitan M.M., Abdelhady M.I.S., Ascrizzi R., Bader A. Proapoptotic Activity of Achillea membranacea Essential Oil and Its Major Constituent 1,8-Cineole against A2780 Ovarian Cancer Cells. Molecules. 2020;25:1582. doi: 10.3390/molecules25071582.", "ArticleIdList": ["10.3390/molecules25071582", "PMC7180961", "32235558"]}, {"Citation": "Chahrour O., Abdalla A., Lam F., Midgley C., Wang S. Synthesis and biological evaluation of benzyl styrylsulfonyl derivatives as potent anticancer mitotic inhibitors. Bioorg. Med. Chem. Lett. 2011;21:3066\u20133069. doi: 10.1016/j.bmcl.2011.03.041.", "ArticleIdList": ["10.1016/j.bmcl.2011.03.041", "21463944"]}, {"Citation": "Gouda A.M., Abdelazeem A.H., Abdalla A.N., Ahmed M. Pyrrolizine-5-carboxamides: Exploring the impact of various substituents on anti-inflammatory and anticancer activities. Acta Pharm. 2018;68:251\u2013273. doi: 10.2478/acph-2018-0026.", "ArticleIdList": ["10.2478/acph-2018-0026", "31259695"]}, {"Citation": "Shaheen U., Ragab E.A., Abdalla A.N., Bader A. Triterpenoidal saponins from the fruits of Gleditsia caspica with proapoptotic properties. Phytochemistry. 2018;145:168\u2013178. doi: 10.1016/j.phytochem.2017.11.007.", "ArticleIdList": ["10.1016/j.phytochem.2017.11.007", "29156366"]}, {"Citation": "Malki W.H., Gouda A.M., Ali H.E.A., Al-Rousan R., Samaha D., Abdalla A.N., Bustamante J., Abd Elmageed Z.Y., Ali H.I. Structural-based design, synthesis, and antitumor activity of novel alloxazine analogues with potential selective kinase inhibition. Eur. J. Med. Chem. 2018;152:31\u201352. doi: 10.1016/j.ejmech.2018.04.029.", "ArticleIdList": ["10.1016/j.ejmech.2018.04.029", "29684708"]}], "ReferenceList": []}], "History": [{"Year": "2020", "Month": "12", "Day": "9"}, {"Year": "2020", "Month": "12", "Day": "30"}, {"Year": "2021", "Month": "1", "Day": "7"}, {"Year": "2021", "Month": "1", "Day": "14", "Hour": "1", "Minute": "1"}, {"Year": "2021", "Month": "1", "Day": "15", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "9", "Day": "11", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "1", "Day": "11"}], "PublicationStatus": "epublish", "ArticleIdList": ["33440689", "PMC7827067", "10.3390/molecules26020334", "molecules26020334"]}}], "PubmedBookArticle": []}